Phase I/II RAF kinase inhibitors in cancer therapy (Q38103961)

28 August 2017

Phase I/II RAF kinase inhibitors in cancer therapy (English)

1 reference

28 August 2017

Samra Turajlic

1

1 reference

28 August 2017

Zohra Ali

series ordinal

2

1 reference

28 August 2017

Nadia Yousaf

series ordinal

3

1 reference

28 August 2017

James Larkin

series ordinal

4

1 reference

28 August 2017

language of work or name

English

0 references

publication date

6 May 2013

1 reference

Expert Opinion on Investigational Drugs

28 August 2017

1 reference

28 August 2017

22

1 reference

28 August 2017

6

1 reference

28 August 2017

739-749

1 reference

Mechanisms of regulating the Raf kinase family

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

BRAF mutations in hairy-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

C-Raf is required for the initiation of lung cancer by K-Ras(G12D).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Regulation and role of Raf-1/B-Raf heterodimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Phase II trial of sorafenib in metastatic thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Initial genome sequencing and analysis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Melanoma brain metastases and vemurafenib: need for further investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

DHODH modulates transcriptional elongation in the neural crest and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Metformin: a diabetes drug for cancer, or a cancer drug for diabetics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

RAF265 inhibits the growth of advanced human melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

Targeting RAF: trials and tribulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

A comprehensive catalogue of somatic mutations from a human cancer genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797964

10.1517/13543784.2013.797964

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference